|4May 10, 5:43 PM ET

BIO-TECHNE Corp 4

4 · BIO-TECHNE Corp · Filed May 10, 2016

Insider Transaction Report

Form 4
Period: 2016-05-09
Transactions
  • Sale

    Common Stock

    2016-05-09$101.91/sh5,000$509,5506,559 total
Holdings
  • Stock Options (Right to Buy)

    Exercise: $87.39From: 2013-10-31Exp: 2023-10-30Common Stock (4,000 underlying)
    4,000
  • Stock Options (Right to Buy)

    Exercise: $65.47From: 2008-10-23Exp: 2018-10-22Common Stock (5,000 underlying)
    5,000
  • Stock Options (Right to Buy)

    Exercise: $63.03From: 2009-10-29Exp: 2019-10-28Common Stock (5,000 underlying)
    5,000
  • Stock Options (Right to Buy)

    Exercise: $61.46From: 2010-10-28Exp: 2020-10-27Common Stock (5,000 underlying)
    5,000
  • Stock Options (Right to Buy)

    Exercise: $70.35From: 2011-10-27Exp: 2021-10-26Common Stock (5,000 underlying)
    5,000
  • Stock Options (Right to Buy)

    Exercise: $66.59From: 2007-10-25Exp: 2017-10-24Common Stock (5,000 underlying)
    5,000
  • Stock Options (Right to Buy)

    Exercise: $91.78From: 2014-10-30Exp: 2024-10-30Common Stock (4,000 underlying)
    4,000
  • Stock Options (Right to Buy)

    Exercise: $87.34From: 2016-10-29Exp: 2025-10-28Common Stock (4,260 underlying)
    4,260
  • Stock Options (Right to Buy)

    Exercise: $66.90From: 2012-10-25Exp: 2022-10-24CommonS tock (5,000 underlying)
    5,000
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.85 to $102.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT